Open AccessEfficacy and Toxicity of Paclitaxel (Taxol) for the Treatment of Canine Malignant Tumors
Author(s) -
Poirier V.J.,
Hershey A.E.,
Burgess K.E.,
Phillips B.,
Turek M.M.,
Forrest L.J.,
Beaver L.,
Vail D.M.
Publication year - 2004
Publication title -
journal of veterinary internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.356
H-Index - 103
eISSN - 1939-1676
pISSN - 0891-6640
DOI - 10.1111/j.1939-1676.2004.tb00164.x
Subject(s) - medicine , neutropenia , paclitaxel , premedication , toxicity , malignant histiocytosis , sepsis , canine lymphoma , osteosarcoma , chemotherapy , gastroenterology , surgery , pathology , histiocyte
Paclitaxel (Taxol ®) was administered to 25 dogs with histologically confirmed malignant tumors at a dosage of 165 mg/m 2 IV over 3–6 hours every 3 weeks. Dogs received premedication with antihistimines and corticosteroids to reduce hypersensitivity reactions. However, 64% of the dogs still experienced allergic reactions. Six dogs (24%) had grade 3 or 4 neutropenia, 6 dogs (24%) required hospitalization and 3 dogs (12%) died of sepsis. Five dogs (20%) had a partial response (osteosarcoma [2 dogs] mammary carcinoma [2 dogs] and malignant histiocytosis [1 dog]) for a median duration of 53 days. The overall toxicity was unacceptable at the 165 mg/m 2 dose. Therefore, subsequent evaluations of paclitaxel in tumor‐bearing dogs should a starting dose of 132 mg/ m 2 IV every 3 weeks.